Relmada Therapeutics News

Relmada Therapeutics Analyst Ratings

BenzingaJun 5 07:21

Goldman Sachs Downgrades Relmada Therapeutics to Sell From Neutral With $2 Price Target

MT NewswiresJun 5 06:16

Buy Rating for Relmada Therapeutics Supported by Strong Clinical Pipeline and Financial Stability

TipRanksMay 10 00:30

Optimistic Outlook for Relmada Therapeutics: A Comprehensive Analysis and Buy Rating

TipRanksMar 21 01:17

Analysts' Opinions Are Mixed on These Healthcare Stocks: Rallybio (RLYB), Avanos Medical (AVNS) and Relmada Therapeutics (RLMD)

TipRanksJan 4 12:10

Relmada Therapeutics: Advancements in MDD and MASLD Programs Bolster Buy Rating

TipRanksNov 10, 2023 05:44

Buy Rating for Relmada Therapeutics: Efficient Management, Promising Trials and Prudent Financial Control

TipRanksNov 9, 2023 13:11

Analysts Offer Insights on Healthcare Companies: AngioDynamics (ANGO), Enlivex (ENLV) and Relmada Therapeutics (RLMD)

TipRanksSep 25, 2023 05:20

Mizuho Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)

TipRanksAug 23, 2023 12:05

Relmada Therapeutics (RLMD) Gets a Buy From Mizuho Securities

TipRanksAug 9, 2023 12:45

Analysts Offer Insights on Healthcare Companies: Verastem (VSTM) and Relmada Therapeutics (RLMD)

TipRanksJun 15, 2023 03:20

SVB Securities Reaffirms Their Buy Rating on Relmada Therapeutics (RLMD)

TipRanksMay 15, 2023 05:05

Mizuho Securities Sticks to Their Buy Rating for Relmada Therapeutics (RLMD)

TipRanksMay 11, 2023 21:15

SVB Securities Sticks to Their Buy Rating for Relmada Therapeutics (RLMD)

TipRanksMar 28, 2023 05:11

SVB Securities Cuts Price Target on Relmada Therapeutics to $10 From $42, Maintains Outperform Rating

MT NewswiresJan 23, 2023 08:20

SVB Securities Keeps Their Buy Rating on Relmada Therapeutics (RLMD)

TipRanksJan 23, 2023 06:30

Relmada Therapeutics Analyst Ratings

Benzinga Analyst RatingsJan 23, 2023 05:21

SVB Leerink Maintains Outperform on Relmada Therapeutics, Lowers Price Target to $10

Benzinga Real-time NewsJan 23, 2023 05:21

Mizuho Securities Sticks to Their Buy Rating for Relmada Therapeutics (RLMD)

TipRanksJan 17, 2023 03:20

Oppenheimer Reiterates Relmada Therapeutics Perform Rating, Removes $7 Price Target

MT NewswiresDec 9, 2022 08:40